Peter Meldgaard
Overview
Explore the profile of Peter Meldgaard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maansson C, Thomsen L, Stokkebro L, Dissing J, Ulhoi M, Nielsen A, et al.
J Liq Biopsy
. 2025 Mar;
4:100141.
PMID: 40027141
Introduction: Recent studies have demonstrated differences between the fragment length profiles of cell-free DNA (cfDNA) from cancer patients and healthy individuals. This has led to the development of size-selection procedures...
2.
Al Bakir M, Reading J, Gamble S, Rosenthal R, Uddin I, Rowan A, et al.
Nature
. 2025 Feb;
PMID: 39972134
Neoantigen vaccines are under investigation for various cancers, including epidermal growth factor receptor (EGFR)-driven lung cancers. We tracked the phylogenetic history of an EGFR mutant lung cancer treated with erlotinib,...
3.
Greibe E, Sorensen B, Meldgaard P, Hoffmann-Lucke E
J Pharm Biomed Anal
. 2025 Jan;
255():116662.
PMID: 39787847
Osimertinib (AZD9291) is a widely used tyrosine kinase inhibitor for the treatment of non-small cell lung cancer patients with activating EGFR mutations. However, the correlation between dose and efficacy has...
4.
Rasmussen T, Gouliaev A, Jakobsen E, Hjorthaug K, Larsen L, Meldgaard P, et al.
BMC Cancer
. 2024 Nov;
24(1):1423.
PMID: 39558297
Introduction: This study aimed to evaluate the consistency of lung cancer case assessments across multidisciplinary team (MDT) sites in Denmark. The goal was to appraise the comparability of outcomes between...
5.
Andersen J, Johansen J, Urbanska E, Meldgaard P, Hjorth-Hansen P, Kristiansen C, et al.
Lung Cancer Manag
. 2024 May;
13(1):LMT68.
PMID: 38818369
The main purpose of the present study was to investigate the labor market affiliation of NSCLC patients in long-term treatment as well as overall survival and incidence/prevalence. Nationwide retrospective study...
6.
Ording A, Christensen T, Skjoth F, Noble S, Hojen A, Morkved A, et al.
Clin Lung Cancer
. 2024 May;
25(5):407-416.e1.
PMID: 38705834
Background: Venous thromboembolism (VTE) is a common complication in patients starting cancer therapies for non-small-cell lung cancer (NSCLC). We examined the risk and timing of VTE in patients with stage...
7.
Christensen T, Ording A, Skjoth F, Morkved A, Jakobsen E, Meldgaard P, et al.
Interdiscip Cardiovasc Thorac Surg
. 2024 May;
38(5).
PMID: 38702829
Objectives: Venous thromboembolic event (VTE) is a severe complication in patients with lung cancer undergoing thoracic surgery. Nevertheless, because of insufficient evidence, there are no clear guidelines, and VTE prophylaxis...
8.
May T, Clement M, Halait H, Kohlmann A, Kohlmann M, Lai J, et al.
PLoS One
. 2024 Apr;
19(4):e0295987.
PMID: 38593164
Survival rates in non-small cell lung cancer (NSCLC) are low. Detection of circulating tumor DNA in liquid biopsy (plasma) is increasingly used to identify targeted therapies for clinically actionable mutations,...
9.
Nielsen L, Stensgaard S, Meldgaard P, Sorensen B
Cancer Treat Res Commun
. 2024 Mar;
39:100802.
PMID: 38428066
Background: Reliable biomarkers are needed to identify tumor recurrence of non-small cell lung cancer (NSCLC) patients after chemoradiotherapy (CRT) with curative intent. This could improve consolidation therapy of progressing patients....
10.
Maansson C, Thomsen L, Meldgaard P, Nielsen A, Sorensen B
Int J Mol Sci
. 2024 Jan;
25(2).
PMID: 38279243
Multiple studies have shown that cell-free DNA (cfDNA) from cancer patients differ in both fragment length and fragment end motif (FEM) from healthy individuals, yet there is a lack of...